Tuberculosis: advances and challenges in development of new diagnostics and biomarkers

The Lancet Infectious Diseases

Volumn 18, Issue 7, 2018, Pages e199-e210

  Walzl, Gerhard ^a,b   McNerney, Ruth ^c   du Plessis, Nelita ^a,b   Bates, Matthew ^f,g   McHugh, Timothy D ^d   Chegou, Novel N ^a,b   Zumla, Alimuddin ^d,e,f  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF LINCOLN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUBERCULOSTATIC AGENT;

BREATH ANALYSIS; COST BENEFIT ANALYSIS; DIGITAL RADIOGRAPHY; EXTRAPULMONARY TUBERCULOSIS; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MOLECULAR DIAGNOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; TUBERCULOSIS; DIAGNOSTIC TEST; MASS SCREENING; PROCEDURES;

ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; BIOMARKERS; DIAGNOSTIC TESTS, ROUTINE; HUMANS; MASS SCREENING; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

EID: 85044277892     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(18)30111-7     Document Type: Review

References (60)

1. WHO. Global tuberculosis report, 2017. 2017, World Health Organization, Geneva.
2. WHO. Strategic and technical advisory group for tuberculosis report of 10th meeting. 2010, World Health Organization, Geneva.
3. WHO. Chest radiography in tuberculosis detection. Summary of current WHO recommendations and guidance on programmatic approaches. 2016, World Health Organization, Geneva.
4. WHO. Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. 2017, World Health Organization, Geneva.
5. Stop TB Partnership. TB REACH Xpert budget estimation tool. http://www.stoptb.org/global/awards/tbreach/bet.asp (accessed Feb 23, 2018).
6. Dalberg Global Development Advisors. UNITAID end-of-project evaluation: TB GeneXpert—scaling up access to contemporary diagnostics for TB. https://unitaid.eu/assets/TB-Xpert-Evaluation_Report-_Final.pdfl, January–March, 2017 (accessed Feb 23, 2018).
7. Raizada, N, Sachdeva, KS, Sreenivas, A, et al. Feasibility of decentralised deployment of Xpert MTB/RIF test at lower level of health system in India. PLoS One, 9, 2014, e89301.
8. Chakravorty, S, Simmons, AM, Rowneki, M, et al. The New Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio 8 (2017), 00812–00817.
9. Dorman, SE, Schumacher, SG, Alland, D, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis 18 (2017), 76–84.
10. WHO. WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTF/RIF Ultra compared to Xpert MTB/RIF. 2017, World Health Organization, Geneva.
11. Bahr, NC, Nuwagira, E, Evans, EE, et al. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infect Dis 18 (2017), 68–75.
12. Peter, JG, Zijenah, LS, Chanda, D, et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet 387 (2016), 1187–1197.
13. WHO. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy update. 2015, World Health Organization, Geneva.
14. Pai, M, Behr, M, Latent Mycobacterium tuberculosis infection and interferon-gamma release assays. Microbiol Spectr 4 (2016), 1–10.
15. Dheda, K, Limberis, JD, Pietersen, E, et al. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. Lancet Respir Med 5 (2017), 269–281.
16. WHO. Critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. 2017, World Health Organization, Geneva https://www.finddx.org/publication/supplement-critical-concentrations-for-dst-for-tb-drugs/ (accessed Feb 25, 2018).
17. Boyle, D, Tuberculosis, diagnostics technology landscape. May, 2017, 5th edn., 2017, World Health Organization, Geneva.
18. Moure, R, Martin, R, Alcaide, F, Silent mutation in rpoB detected from clinical samples with rifampin-susceptible Mycobacterium tuberculosis. J Clin Microbiol, 49, 2011, 3722.
19. Miotto, P, Tessema, B, Tagliani, E, et al. A standardised method for interpreting the association between mutations and phenotypic drug-resistance in Mycobacterium tuberculosis. Eur Respir J, 50, 2017, 1701354.
20. Xie, YL, Chakravorty, S, Armstrong, DT, et al. Evaluation of a rapid molecular drug-susceptibility test for tuberculosis. N Engl J Med 377 (2017), 1043–1054.
21. Coll, F, Phelan, J, Hill-Cawthorne, GA, et al. Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis. Nat Genet 50 (2018), 307–316.
22. McNerney, R, Clark, TG, Campino, S, et al. Removing the bottleneck in whole genome sequencing of Mycobacterium tuberculosis for rapid drug resistance analysis: a call to action. Int J Infect Dis 56 (2017), 130–135.
23. Olaru, ID, Patel, H, Kranzer, K, Perera, N, Turnaround time of whole genome sequencing for mycobacterial identification and drug susceptibility testing in routine practice. Clin Microbiol Infect, 2017 published online Oct 10. DOI:10.1016/j.cmi.2017.10.001.
24. Lessem, E, The tuberculosis diagnostics pipeline. http://www.pipelinereport.org/2017/tbdx, July, 2017 (accessed Feb 23, 2018).
25. FIND. Dx Pipeline. https://www.finddx.org/dx-pipeline-status/ (accessed Feb 23, 2018).
26. Paris, L, Magni, R, Zaidi, F, et al. Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity. Sci Transl Med, 9, 2017, eaal2807.
27. Liu, C, Zhao, Z, Fan, J, et al. Quantification of circulating Mycobacterium tuberculosis antigen peptides allows rapid diagnosis of active disease and treatment monitoring. Proc Natl Acad Sci USA 114 (2017), 3969–3974.
28. Global Laboratory Initiative. GLI quick guide to TB diagnostics connectivity solution. http://www.stoptb.org/wg/gli/assets/documents/gli_connectivity_guide.pdf, October, 2016 (accessed Feb 23, 2018).
29. WHO. Commercial serodiagnostic tests for diagnosis of tuberculosis. 2011, World Health Organization, Geneva.
30. Zak, DE, Penn-Nicholson, A, Scriba, TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 387 (2016), 2312–2322.
31. Berry, MP, Graham, CM, McNab, FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466 (2010), 973–977.
32. Laux da Costa, L, Delcroix, M, Dalla Costa, ER, et al. A real-time PCR signature to discriminate between tuberculosis and other pulmonary diseases. Tuberculosis (Edinb) 95 (2015), 421–425.
33. Kaforou, M, Wright, VJ, Oni, T, et al. Detection of tuberculosis in HIV-infected and -uninfected African adults using whole blood RNA expression signatures: a case-control study. PLoS Med, 10, 2013, e1001538.
34. Sutherland, JS, Loxton, AG, Haks, MC, et al. Differential gene expression of activating Fcγ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clin Microbiol Infect 20 (2014), O230–O238.
35. Maertzdorf, J, McEwen, G, Weiner, J 3rd, et al. Concise gene signature for point-of-care classification of tuberculosis. EMBO Mol Med 8 (2016), 86–95.
36. Diaceutics. How much does it cost to launch and commercialize a companion diagnostic test?. http://www.diaceutics.com/2016/08/31/how-much-does-it-cost-to-launch-and-commercialize-a-companion-diagnostic-test/, Aug 31, 2016 (accessed Dec 12, 2017).
37. Yoon, C, Semitala, FC, Atuhumuza, E, et al. Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study. Lancet Infect Dis 7 (2017), 1285–1292.
38. Chegou, NN, Heyckendorf, J, Walzl, G, Lange, C, Ruhwald, M, Beyond the IFN-γ horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis. Eur Respir J 43 (2014), 1472–1486.
39. De Groote, MA, Sterling, DG, Hraha, T, et al. Discovery and validation of a six-marker serum protein signature for the diagnosis of active pulmonary tuberculosis. J Clin Microbiol 55 (2017), 3057–3071.
40. 1 H NMR spectroscopy. Tuberculosis (Edinb) 95 (2015), 294–302.
41. Weiner, J 3rd, Parida, SK, Maertzdorf, J, et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One, 7, 2012, e40221.
42. du Preez, I, Loots, DT, New sputum metabolite markers implicating adaptations of the host to Mycobacterium tuberculosis, and vice versa. Tuberculosis (Edinb) 93 (2013), 330–337.
43. Frediani, JK, Jones, DP, Tukvadze, N, et al. Plasma metabolomics in human pulmonary tuberculosis disease: a pilot study. PLoS One, 9, 2014, e108854.
44. Lau, SK, Lee, KC, Curreem, SO, et al. Metabolomic profiling of plasma from patients with tuberculosis by use of untargeted mass spectrometry reveals novel biomarkers for diagnosis. J Clin Microbiol 53 (2015), 3750–3759.
45. Zhang, H, Sun, Z, Wei, W, et al. Identification of serum microRNA biomarkers for tuberculosis using RNA-seq. PLoS One, 9, 2014, e88909.
46. Latorre, I, Leidinger, P, Backes, C, et al. A novel whole-blood miRNA signature for a rapid diagnosis of pulmonary tuberculosis. Eur Respir J 45 (2015), 1173–1176.
47. Cui, JY, Liang, HW, Pan, XL, et al. Characterization of a novel panel of plasma microRNAs that discriminates between Mycobacterium tuberculosis infection and healthy individuals. PLoS One, 12, 2017, e0184113.
48. Scriba, TJ, Penn-Nicholson, A, Shankar, S, et al. Sequential inflammatory processes define human progression from M tuberculosis infection to tuberculosis disease. PLoS Pathog, 13, 2017, e1006687.
49. Maertzdorf, J, Repsilber, D, Parida, SK, et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 12 (2011), 15–22.
50. Bloom, CI, Graham, CM, Berry, MP, et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One, 8, 2013, e70630.
51. Anderson, ST, Kaforou, M, Brent, AJ, et al. Diagnosis of childhood tuberculosis and host RNA expression in Africa. N Engl J Med 370 (2014), 1712–1723.
52. Sackett, DL, Haynes, RB, The architecture of diagnostic research. BMJ 324 (2002), 539–541.
53. Chegou, NN, Sutherland, JS, Malherbe, S, et al. Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB. Thorax 71 (2016), 785–794.
54. 1 H NMR spectroscopy-based metabolomics to sera of tuberculosis patients. J Proteome Res 12 (2013), 4642–4649.
55. Mahapatra, S, Hess, AM, Johnson, JL, et al. A metabolic biosignature of early response to anti-tuberculosis treatment. BMC Infect Dis, 14, 2014, 53.
56. 1 H-nuclear magnetic resonance spectroscopy metabolic profiles in tuberculous, malignant and transudative pleural effusion. Mol Med Rep 16 (2017), 1147–1156.
57. Zimmermann, M, Kogadeeva, M, Gengenbacher, M, et al. Integration of metabolomics and transcriptomics reveals a complex diet of Mycobacterium tuberculosis during early macrophage infection. mSystems 2 (2017), e00057–e00117.
58. Skoura, E, Zumla, A, Bomanji, J, Imaging in tuberculosis. Int J Infect Dis 32 (2015), 87–93.
59. WHO. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. 2014, World Health Organization, Geneva.
60. WHO. Moscow Declaration to End TB. http://www.who.int/tb/features_archive/Moscow_Declaration_to_End_TB_final_ENGLISH.pdf?ua=1, Nov 16–17, 2017 (accessed Feb 25, 2018).